JP Morgan Chase
XENE icon

JP Morgan Chase’s Xenon Pharmaceuticals XENE Stock Holding History

JP Morgan Chase’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107M Buy
1,923,610
+429,578
+29% +$19.8M 0.01% 948
2025
Q4 		$67M Buy
1,494,032
+94,999
+7% +$3.99M ﹤0.01% 1177
2025
Q3 		$56.2M Buy
1,399,033
+142,452
+11% +$5.02M ﹤0.01% 1342
2025
Q2 		$39.3M Sell
1,256,581
-101,021
-7% -$3.3M ﹤0.01% 1476
2025
Q1 		$45.5M Buy
1,357,602
+707
+0.1% +$26.8K ﹤0.01% 1360
2024
Q4 		$53.2M Buy
1,356,895
+380,112
+39% +$15.7M ﹤0.01% 1286
2024
Q3 		$38.5M Buy
976,783
+905,129
+1,263% +$36.5M ﹤0.01% 1498
2024
Q2 		$2.79M Buy
71,654
+35,033
+96% +$1.4M ﹤0.01% 3497
2024
Q1 		$1.58M Sell
36,621
-16,167
-31% -$744K ﹤0.01% 4032
2023
Q4 		$2.43M Buy
52,788
+2,491
+5% +$88K ﹤0.01% 3687
2023
Q3 		$1.72M Sell
50,297
-28,920
-37% -$1.08M ﹤0.01% 3655
2023
Q2 		$3.05M Buy
79,217
+46,430
+142% +$1.85M ﹤0.01% 3240
2023
Q1 		$1.17M Buy
32,787
+30,700
+1,471% +$1.13M ﹤0.01% 3940
2022
Q4 		$82K Sell
2,087
-2,184
-51% -$79.5K ﹤0.01% 5429
2022
Q3 		$155K Buy
4,271
+1,825
+75% +$65.6K ﹤0.01% 5068
2022
Q2 		$74K Sell
2,446
-3,925
-62% -$119K ﹤0.01% 5541
2022
Q1 		$194K Buy
6,371
+1,596
+33% +$47.8K ﹤0.01% 5208
2021
Q4 		$149K Buy
4,775
+1,761
+58% +$52.6K ﹤0.01% 5503
2021
Q3 		$46K Buy
3,014
+975
+48% +$16.9K ﹤0.01% 5864
2021
Q2 		$38K Sell
2,039
-4,466
-69% -$82.3K ﹤0.01% 5810
2021
Q1 		$116K Buy
6,505
+6,447
+11,116% +$109K ﹤0.01% 5338
2020
Q4 		$1K Buy
+58
New +$679 ﹤0.01% 5569
2020
Q3 		– Sell
-96,372
Closed -$1.21M – 5824
2020
Q2 		$1.21M Buy
96,372
+46,253
+92% +$589K ﹤0.01% 3406
2020
Q1 		$568K Sell
50,119
-8,474
-14% -$121K ﹤0.01% 3758
2019
Q4 		$768K Buy
58,593
+37,461
+177% +$394K ﹤0.01% 4019
2019
Q3 		$190K Sell
21,132
-12,462
-37% -$118K ﹤0.01% 4656
2019
Q2 		$332K Sell
33,594
-62,810
-65% -$601K ﹤0.01% 4428
2019
Q1 		$979K Sell
96,404
-93,407
-49% -$792K ﹤0.01% 3818
2018
Q4 		$1.2M Buy
189,811
+181,381
+2,152% +$1.61M ﹤0.01% 3626
2018
Q3 		$111K Buy
+8,430
New +$97.7K ﹤0.01% 4910
2017
Q4 		– Sell
-9,226
Closed -$27K – 5604
2017
Q3 		$27K Sell
9,226
-1,590
-15% -$4.92K ﹤0.01% 4590
2017
Q2 		$34K Buy
10,816
+7,200
+199% +$28.1K ﹤0.01% 4424
2017
Q1 		$14K Buy
+3,616
New +$28.4K ﹤0.01% 4760
2016
Q4 		– Sell
-1,700
Closed -$14K – 5153
2016
Q3 		$14K Buy
1,700
+1,589
+1,432% +$12.3K ﹤0.01% 4252
2016
Q2 		$1K Buy
+111
New +$761 ﹤0.01% 4699

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's XENE Position: Q1 2026 in Review

JP Morgan Chase increased its Xenon Pharmaceuticals (XENE) stake by 29% in Q1 2026, buying an estimated $19.8M and bringing the position to 1,923,610 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #948.

JP Morgan Chase first reported a position in XENE in Q2 2016 and has held it in 35 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • JP Morgan Chase held 1,923,610 shares of Xenon Pharmaceuticals worth $107M as of Q1 2026.
  • JP Morgan Chase bought 429,578 Xenon Pharmaceuticals shares in Q1 2026, an estimated $19.8M.
  • Xenon Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #948 holding.
  • JP Morgan Chase first reported a position in Xenon Pharmaceuticals in Q2 2016 and has held it in 35 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.